|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.75 GBX | +1.02% |
|
-0.78% | -61.59% |
| 05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
| 05-01 | Avacta picks Christina Coughlin to replace long-serving CEO | AN |
In the second episode of our R&D Spotlight series we are fast forwarding into the clinic and talking to two members of the Avacta translational medicine team.
Attachments
Disclaimer
Avacta Group plc published this content on 25 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2024 13:46:06 UTC.
| 1st Jan change | Capi. | |
|---|---|---|
| -61.59% | 198M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
AVACTA GROUP PLC 
